Organon & Co. (OGN)
After hours:
| Previous close | 11.32 |
| Open | 11.33 |
| Bid | 11.44 x 1300 |
| Ask | 11.53 x 900 |
| Day's range | 11.22 - 11.72 |
| 52-week range | 10.90 - 32.43 |
| Volume | |
| Avg. volume | 4,866,876 |
| Market cap | 2.939B |
| Beta (5Y monthly) | 0.91 |
| PE ratio (TTM) | 5.04 |
| EPS (TTM) | 2.28 |
| Earnings date | 05 Feb 2024 - 09 Feb 2024 |
| Forward dividend & yield | 1.12 (9.74%) |
| Ex-dividend date | 10 Nov 2023 |
| 1y target est | 21.00 |
Business WireOrganon To Present at the Piper Sandler 35th Annual Healthcare Conference
JERSEY CITY, N.J., November 21, 2023--Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023 at 11:00 a.m. EST.
GlobeNewswireSamsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (adalimumab-bwwd), a Biosimilar to Humira®
sBLA based on Phase 4 study which assessed pharmacokinetic similarity between two treatment groups: multi-switching group alternating between Humira and high-concentration HADLIMA vs. Humira-continued groupFiling acceptance reinforces Samsung Bioepis and Organon’s commitment to provide better access to biologic medicines for patients in the United States INCHEON, South Korea and JERSEY CITY, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today ann
Business WireOrganon Reports Results for the Third Quarter Ended September 30, 2023
JERSEY CITY, N.J., November 02, 2023--Organon Reports Results for the Third Quarter Ended September 30, 2023
